We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.
- Authors
Redana S; Donadio M; Nolè F; Jacomuzzi ME; Beano A; Martinello R; Sapino A; Viale G; Aglietta M; Montemurro F; Redana, Stefania; Donadio, Michela; Nolè, Franco; Jacomuzzi, Maria Elena; Beano, Alessandra; Martinello, Rossella; Sapino, Anna; Viale, Giuseppe; Aglietta, Massimo; Montemurro, Filippo
- Abstract
<bold>Background: </bold>Combinations of trastuzumab with either docetaxel or vinorelbine are considered valuable treatment options for HER2-positive metastatic breast cancer patients. We performed a retrospective comparison of the clinical outcomes associated with either one of these combinations.<bold>Methods: </bold>From a multi-institutional database we retrieved 179 patients treated with either docetaxel or vinorelbine plus trastuzumab as first-line therapy for HER2-positive advanced breast cancer.<bold>Results: </bold>Docetaxel-trastuzumab was superior to vinorelbine-trastuzumab in terms of response rate (RR: 77 vs 57%, p = 0.01) and median overall survival (OS: 35 vs 23 months, p = 0.04), but not in median time to progression (TTP: 12 vs 10 months, p = 0.53). At multivariate analysis, type of treatment was not associated with TTP but was an independent predictor of OS, with a significant reduction in the risk of death in favor of docetaxel-trastuzumab (HR 0.474, 95% IC 0,303-0.742, p < 0.01).<bold>Conclusion: </bold>Docetaxel or vinorelbine, when combined with trastuzumab, provide excellent rates of tumor control in patients with previously untreated HER2-positive advanced breast cancer. Docetaxel may offer some advantage in terms of response rate and resulted in a significantly prolonged overall survival, which, because of the retrospective design of our study, deserves further investigation in prospective trials.
- Publication
BMC Cancer, 2010, Vol 10, p28
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/1471-2407-10-28